|
|
|
18.06.25 - 23:03
|
Satellos Bioscience Shareholders Elect Two New Board Members (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced the election of Iris Loew-Friedrich, M.D., Ph.D., and Selwyn Ho, MBBS, to its Board of Directors.
“I am so excited to welcome Dr. Loew-Friedrich and Dr. Ho to our Board at this pivotal time,” said Frank Gleeson, Satellos co-founder and CEO. “We believe their deep expertise in global clinical and commercial development will be invaluable to Satellos as we advance SAT-3247 and realize our technology's transformative potential for the treatment of people living with Duchenne muscular dystrophy and other degenerative conditions. We look forward to drawing on their proven expertise in positioning Satellos for future partnerships and development strategies focused on delivering optimal value for shareholders.”
A highly accomplished biotech and p...
|
|
|
18.06.25 - 23:03
|
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders (Business Wire)
|
|
|
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, announced today the results of its Annual and Special Meeting of Shareholders held June 18, 2025 (the “Meeting”).
Satellos is pleased to announce that all the nominees listed in the management information circular dated May 12, 2025 (the “Circular”), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy with a total of 41.15% of the issued and outstanding common shares of the Company represented in person and by proxy at the Meeting.
The results of the vote are detailed below:
Director
Votes For
% For
Votes Against
% Against
Frank Gleeson
56,671,162
99.99
5,404
0.01
Franklin M. Berger
55,208,162
97.41
1,468,404
2.59
Brian Bloom
56,655,657
99.96
20,909
0.04...
|
|
|
|
|
|
|
13.05.25 - 13:06
|
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress (Business Wire)
|
|
|
- Completed enrollment in the Phase 1b trial in adult patients with Duchenne muscular dystrophy (DMD); data analysis and reporting expected in Q2 2025
- Received regulatory approval, allowing initiation of a long-term follow-up study to treat DMD patients from the Phase 1b for 11 additional months
- Profile of SAT-3247, presented at the Muscular Dystrophy Association (MDA) Conference, demonstrated the drug to be safe and well tolerated with a predictable pharmacokinetic (PK) profile in healthy volunteers
- Global regulatory filings to obtain approvals to initiate a Ph 2 randomized, placebo-controlled proof-of-concept clinical (POC) trial in pediatric DMD patients expected to be submitted in Q3 2025
- Funds available: $41.2 million (in $U.S.) as of March 31, 2025, expected to be sufficient to fund company operations, including study costs through completion of the planned Phase 2 POC clinical trial
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Compan...
|
|
|
|
|
26.03.25 - 12:03
|
Satellos Reports 2024 Financial Results and Highlights Company Progress (Business Wire)
|
|
|
– Completed enrollment and dosing in a Phase 1a clinical trial in 72 healthy volunteers to assess safety and pharmacokinetic (PK) properties of SAT-3247
– Presented initial Phase 1a data at Muscular Dystrophy Association (MDA) Clinical & Scientific Conference showing SAT-3247 was safe, well-tolerated and showed the intended PK profile after both single- and repeated-dose administration
– Initiated enrollment in a Phase 1b clinical trial in up to 10 adults with Duchenne muscular dystrophy (DMD) with data expected to be reported in Q2 2025
– Cash balance of $69.9 million as of December 31, 2024
TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, announced today its financial results and corporate highlights for the fourth quarter ended December 31, 2024. All references to currency in this press release are in Canadian dollar...
|
|
|
|
|
18.12.24 - 08:27
|
XFRA : 0ITA: Wiederaufnahme/Resumption (XETRA)
|
|
|
FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.
THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN
SATELLOS BIOSCIENCE INC. 0ITA CA80401L3083
AB/FROM ONWARDS 18.12.2024...
|
|
|
17.12.24 - 08:17
|
XFRA : 0ITA: Aussetzung/Suspension (XETRA)
|
|
|
DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:
THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:
INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL
SATELLOS BIOSCIENCE INC. 0ITA CA80401L3083 BAW/UFN...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
